middle.news
Mayne Pharma Doubles EBITDA on 5% Revenue Growth, Launches New Dermatology Drugs
3:59am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
Mayne Pharma Doubles EBITDA on 5% Revenue Growth, Launches New Dermatology Drugs
3:59am on Saturday 30th of August, 2025 AEST
Key Points
Revenue rises 5% to A$408.1 million
Underlying EBITDA doubles to A$47.0 million
Women’s Health segment grows 23%, driving margin expansion
Acquisition and launch of TWYNEO® and EPSOLAY® dermatology products
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mayne Pharma (ASX:MYX)
OPEN ARTICLE